USMLE Step 1 & 2 DNA/RNA Replication, Transcription, Translation

Last updated: May 2, 2026

DNA/RNA Replication, Transcription, Translation questions are one of the highest-leverage areas to study for the USMLE Step 1 & 2. This guide breaks down the rule, the elements you need to recognize, the named traps that catch most students, and a memory aid that scales to test day. Read it once, then practice the same sub-topic adaptively in the app.

The rule

DNA replication, transcription, and translation each rely on a distinct set of enzymes and substrates that the USMLE tests by mechanism, directionality, and drug target. Every nucleic-acid polymerase reads its template 3' to 5' and synthesizes the new strand 5' to 3', requires a free 3'-OH for the next phosphodiester bond, and uses a specific subset of cofactors. Translation, by contrast, reads mRNA 5' to 3' and builds protein N-terminus to C-terminus on a ribosome whose A, P, and E sites are the targets of most clinically important antibiotics. When you see an enzyme name, a directional clue, or an antibiotic, map it back to which of the three steps is being interrupted.

Elements breakdown

DNA replication enzymes (eukaryotic)

The machinery that duplicates the genome at the replication fork, semiconservatively and bidirectionally.

  • helicase unwinds dsDNA at origin
  • topoisomerase II relieves supercoils
  • SSBs stabilize unwound strands
  • primase lays RNA primer
  • Pol α extends primer briefly
  • Pol δ synthesizes lagging strand
  • Pol ε synthesizes leading strand
  • FEN1 removes RNA primer
  • DNA ligase seals nicks
  • telomerase extends 3' ends

Common examples:

  • fluoroquinolones inhibit prokaryotic topoisomerase II (gyrase) and IV
  • etoposide stabilizes topoisomerase II–DNA complex

DNA repair pathways (high-yield)

Distinct pathways that fix specific lesion types; each is linked to a hereditary syndrome.

  • nucleotide excision repair fixes pyrimidine dimers
  • base excision repair fixes single damaged bases
  • mismatch repair fixes replication errors
  • nonhomologous end joining seals dsDNA breaks
  • homologous recombination uses sister chromatid

Common examples:

  • xeroderma pigmentosum = NER defect
  • HNPCC/Lynch = MMR (MSH2, MLH1) defect
  • BRCA1/2 = HR defect
  • ataxia-telangiectasia = ATM (DSB sensing) defect

Transcription (eukaryotic RNA polymerases)

DNA-dependent RNA synthesis; three nuclear polymerases each transcribe a distinct RNA class.

  • RNA Pol I: rRNA (45S precursor)
  • RNA Pol II: mRNA, snRNA
  • RNA Pol III: tRNA, 5S rRNA
  • TATA box at –25 binds TFIID
  • α-amanitin selectively inhibits Pol II
  • actinomycin D inhibits all polymerases

Common examples:

  • Amanita phalloides ingestion → hepatotoxic Pol II shutdown
  • rifampin inhibits prokaryotic RNA polymerase

mRNA processing (eukaryotic)

Three covalent modifications turn pre-mRNA into translation-competent mRNA, all in the nucleus.

  • 5' 7-methylguanosine cap
  • 3' poly-A tail by poly-A polymerase
  • spliceosome removes introns at GU-AG
  • alternative splicing generates isoforms
  • anti-snRNP antibodies in lupus/MCTD

Translation machinery

Ribosomal protein synthesis using mRNA codons, charged tRNAs, and three ribosomal sites.

  • eukaryotic ribosome 80S (60S + 40S)
  • prokaryotic ribosome 70S (50S + 30S)
  • A site: incoming aminoacyl-tRNA
  • P site: peptidyl-tRNA, growing chain
  • E site: exit of deacylated tRNA
  • peptidyl transferase = 23S rRNA (ribozyme)
  • GTP hydrolysis at initiation, elongation, translocation
  • start codon AUG = Met (eukaryote) / fMet (prokaryote)

Common examples:

  • aminoglycosides → 30S, misreading
  • tetracyclines → 30S, block A-site tRNA
  • chloramphenicol → 50S peptidyl transferase
  • macrolides/clindamycin/linezolid → 50S translocation
  • diphtheria/pseudomonas exotoxin → ADP-ribosylates EF-2
  • shiga/shiga-like toxin → cleaves 60S 28S rRNA

Common patterns and traps

The Antibiotic-to-Subunit Map

USMLE writers love presenting a bacterial infection plus an antibiotic mechanism description and asking which step of protein synthesis is blocked. The trap is mismatching 30S agents (aminoglycosides, tetracyclines) with 50S agents (chloramphenicol, clindamycin, macrolides, linezolid, streptogramins). Mechanism cues — "misreading," "blocks A-site," "inhibits peptidyl transferase," "blocks translocation" — each point to a specific drug class.

A choice naming the wrong subunit (e.g., "30S inhibition causing misreading" when the drug is actually erythromycin acting on 50S).

The Polymerase Directionality Trap

Every DNA and RNA polymerase reads template 3'→5' and synthesizes 5'→3', requiring a free 3'-OH. Distractors invert the direction or claim a polymerase can add to the 5' end. The same trap applies to translation: ribosomes read mRNA 5'→3' but assemble protein N→C, and choices may scramble those pairings.

A choice describing "DNA polymerase extending the new strand 3' to 5'" or "ribosome reading mRNA 3' to 5' to synthesize protein C-terminus to N-terminus."

The Repair Pathway–Syndrome Pairing

Each hereditary repair-defect syndrome locks to a specific lesion type and pathway: xeroderma pigmentosum/NER/UV dimers; HNPCC/MMR/microsatellite instability; BRCA/HR/double-strand breaks; ataxia-telangiectasia/ATM/DSB sensing. Stems hide the pathway in the clinical clue (sun-exposed skin cancers in childhood, family history of colon cancer at young age, breast/ovarian cancer cluster).

A choice that names a real repair pathway but the wrong one for the lesion described, e.g., picking "base excision repair" for a patient with severe photosensitivity.

The Toxin Target Switch

Toxins that look similar are tested on the precise step they disable. Diphtheria and pseudomonas exotoxin A both ADP-ribosylate EF-2 (translation elongation). Shiga and shiga-like toxin cleave the 60S 28S rRNA (translation, not transcription). α-Amanitin blocks RNA Pol II (transcription). Ricin removes an adenine from 28S rRNA. Mixing up "transcription block" with "translation block" is the classic miss.

A choice claiming diphtheria toxin "inhibits RNA polymerase II" or shiga toxin "prevents tRNA charging."

The mRNA Processing Distractor

Questions about splicing, capping, and polyadenylation often offer distractors that describe a real process at the wrong organelle, wrong substrate, or wrong stage. Splicing happens in the nucleus on pre-mRNA, the spliceosome recognizes GU at the 5' donor and AG at the 3' acceptor, and snRNPs are the targets of anti-Smith antibodies in SLE.

A choice describing "cytoplasmic intron removal" or "poly-A tail addition by RNA polymerase II during elongation."

How it works

Picture a stem in which an oncology patient on etoposide develops a secondary AML, or a hiker who ate wild mushrooms presents with hepatic failure. Your job is to map the agent to its molecular step. Etoposide jams topoisomerase II during replication, causing double-strand breaks; α-amanitin from Amanita phalloides shuts down RNA Pol II, stopping mRNA synthesis in the liver. The same logic applies to antibiotics: when the question says "binds the 30S subunit and causes misreading," you should think aminoglycoside before reading the choices. Direction matters too — if a stem says a polymerase "adds nucleotides to the 5' end of the growing chain," that's a distractor, because every polymerase you'll be tested on extends the 3' end. Repair questions hinge on lesion type: UV-induced thymine dimers → NER → xeroderma pigmentosum; microsatellite instability in colon cancer → MMR → Lynch syndrome.

Worked examples

Worked Example 1

The toxin responsible for this patient's hepatic failure most directly inhibits which of the following processes?

  • A Synthesis of ribosomal RNA by RNA polymerase I
  • B Synthesis of messenger RNA by RNA polymerase II ✓ Correct
  • C Translocation of peptidyl-tRNA from the A site to the P site of the 60S ribosomal subunit
  • D Removal of the RNA primer from Okazaki fragments during DNA replication

Why B is correct: The biphasic course (early GI symptoms, then delayed fulminant hepatitis 24–48 hours later) plus wild-mushroom ingestion is the classic Amanita phalloides presentation. Its principal toxin, α-amanitin, selectively and potently inhibits eukaryotic RNA polymerase II, halting mRNA synthesis. Hepatocytes — with their high transcriptional demand — die first, producing the massive transaminase elevation, coagulopathy, and hyperammonemia seen here.

Why each wrong choice fails:

  • A: RNA polymerase I synthesizes the 45S rRNA precursor in the nucleolus and is not the target of α-amanitin at clinically relevant doses; only Pol II is highly sensitive. A candidate who remembers "amanitin blocks transcription" but not which polymerase gets fooled here. (The Toxin Target Switch)
  • C: Translocation on the 60S subunit is blocked by macrolides, clindamycin, and linezolid — not by mushroom toxins. A test-taker who confuses transcription inhibition with translation inhibition would land here. (The Antibiotic-to-Subunit Map)
  • D: RNA primer removal during lagging-strand synthesis is performed by FEN1 and RNase H during DNA replication and is unrelated to amanitin's mechanism. This distractor catches candidates who pattern-match "RNA" without distinguishing transcription from replication. (The Polymerase Directionality Trap)
Worked Example 2

The novel antibiotic most likely belongs to the same drug class as which of the following agents?

  • A Erythromycin
  • B Gentamicin ✓ Correct
  • C Chloramphenicol
  • D Linezolid

Why B is correct: A 30S-binding antibiotic that causes mRNA misreading is the defining mechanism of aminoglycosides, of which gentamicin is the prototype. Tetracyclines also bind 30S but block A-site tRNA entry without misreading, exactly as the stem describes. The misreading versus blocking distinction is the high-yield way to separate the two 30S classes.

Why each wrong choice fails:

  • A: Erythromycin is a macrolide and binds the 50S subunit, blocking translocation. The stem specifies 30S binding, which rules it out despite the candidate temptation to lump all "protein-synthesis inhibitors" together. (The Antibiotic-to-Subunit Map)
  • C: Chloramphenicol binds 50S and inhibits peptidyl transferase activity, not 30S misreading. Easily confused if the candidate forgets the subunit assignments. (The Antibiotic-to-Subunit Map)
  • D: Linezolid binds 50S and prevents formation of the initiation complex; it does not act at 30S and does not cause misreading. Picking it reflects a vague memory that linezolid is "a newer protein-synthesis inhibitor" without the mechanism nailed down. (The Antibiotic-to-Subunit Map)
Worked Example 3

A defect in which of the following DNA repair processes best explains these findings?

  • A Mismatch repair
  • B Base excision repair
  • C Nucleotide excision repair ✓ Correct
  • D Nonhomologous end joining

Why C is correct: Childhood photosensitivity, early skin cancers in sun-exposed areas, and a fibroblast assay showing failure to excise UV-induced pyrimidine dimers is xeroderma pigmentosum. XP is caused by autosomal recessive defects in the nucleotide excision repair pathway, which normally recognizes and removes bulky helix-distorting lesions including thymine dimers. Consanguinity (second-cousin parents) raises pretest probability for autosomal recessive disease.

Why each wrong choice fails:

  • A: Mismatch repair corrects base–base mispairs and small insertion/deletion loops introduced during replication; defects cause Lynch syndrome (HNPCC) with early colorectal and endometrial cancer, not UV photosensitivity. The clinical picture and assay clearly point to UV-lesion repair, not replication-error correction. (The Repair Pathway–Syndrome Pairing)
  • B: Base excision repair removes single damaged or inappropriate bases (such as deaminated cytosine or oxidized guanine) using DNA glycosylases, not bulky dimers. A candidate who knows BER handles "DNA damage" without specifying lesion type might pick this distractor. (The Repair Pathway–Syndrome Pairing)
  • D: Nonhomologous end joining repairs double-strand breaks and is defective in syndromes like ataxia-telangiectasia (ATM) and certain SCIDs, not in XP. Pyrimidine dimers are not double-strand breaks, so NHEJ is the wrong pathway for the assay finding described. (The Repair Pathway–Syndrome Pairing)

Memory aid

"I eat (1) PB&J (2) with Tea (3)" — Pol I = rRNA, Pol II = mRNA, Pol III = tRNA. For ribosomes: "Buy AT 30, CCEL at 50" — Aminoglycosides + Tetracyclines hit 30S; Chloramphenicol, Clindamycin, Erythromycin (macrolides), Linezolid hit 50S.

Key distinction

Distinguish RNA Pol II inhibition (α-amanitin, hepatotoxic, blocks mRNA only) from total transcription arrest (actinomycin D, all three polymerases) and from prokaryotic RNA polymerase inhibition (rifampin, used for TB and meningococcal prophylaxis). Each maps to a different clinical scenario but all three "stop transcription."

Summary

USMLE central dogma items reward you for mapping every drug, toxin, or hereditary syndrome to the precise enzyme, subunit, or repair pathway it disables.

Practice dna/rna replication, transcription, translation adaptively

Reading the rule is the start. Working USMLE Step 1 & 2-format questions on this sub-topic with adaptive selection, watching your mastery score climb in real time, and seeing the items you missed return on a spaced-repetition schedule — that's where score lift actually happens. Free for seven days. No credit card required.

Start your free 7-day trial

Frequently asked questions

What is dna/rna replication, transcription, translation on the USMLE Step 1 & 2?

DNA replication, transcription, and translation each rely on a distinct set of enzymes and substrates that the USMLE tests by mechanism, directionality, and drug target. Every nucleic-acid polymerase reads its template 3' to 5' and synthesizes the new strand 5' to 3', requires a free 3'-OH for the next phosphodiester bond, and uses a specific subset of cofactors. Translation, by contrast, reads mRNA 5' to 3' and builds protein N-terminus to C-terminus on a ribosome whose A, P, and E sites are the targets of most clinically important antibiotics. When you see an enzyme name, a directional clue, or an antibiotic, map it back to which of the three steps is being interrupted.

How do I practice dna/rna replication, transcription, translation questions?

The fastest way to improve on dna/rna replication, transcription, translation is targeted, adaptive practice — working questions that focus on your specific weak spots within this sub-topic, getting immediate feedback, and revisiting items you missed on a spaced-repetition schedule. Neureto's adaptive engine does this automatically across the USMLE Step 1 & 2; start a free 7-day trial to see your sub-topic mastery climb in real time.

What's the most important distinction to remember for dna/rna replication, transcription, translation?

Distinguish RNA Pol II inhibition (α-amanitin, hepatotoxic, blocks mRNA only) from total transcription arrest (actinomycin D, all three polymerases) and from prokaryotic RNA polymerase inhibition (rifampin, used for TB and meningococcal prophylaxis). Each maps to a different clinical scenario but all three "stop transcription."

Is there a memory aid for dna/rna replication, transcription, translation questions?

"I eat (1) PB&J (2) with Tea (3)" — Pol I = rRNA, Pol II = mRNA, Pol III = tRNA. For ribosomes: "Buy AT 30, CCEL at 50" — Aminoglycosides + Tetracyclines hit 30S; Chloramphenicol, Clindamycin, Erythromycin (macrolides), Linezolid hit 50S.

What's a common trap on dna/rna replication, transcription, translation questions?

Confusing prokaryotic and eukaryotic ribosome subunits when matching antibiotics

What's a common trap on dna/rna replication, transcription, translation questions?

Picking the wrong RNA polymerase for the RNA species being synthesized

Related USMLE Step 1 & 2 sub-topics

Ready to drill these patterns?

Take a free USMLE Step 1 & 2 assessment — about 25 minutes and Neureto will route more dna/rna replication, transcription, translation questions your way until your sub-topic mastery score reflects real improvement, not luck. Free for seven days. No credit card required.

Start your free 7-day trial